The Diaz Lab is interested in developing targeted therapeutics for the treatment of glioma. We apply molecular and computational approaches to elucidate targets and pathways mediating cancer progression. To date, some of the most effective cancer therapies have been those that hone in on molecular defects associated with specific driver genes. However, in highly diverse tumors, such as gliomas, clinical trials of promising targeted therapeutics often produce mixed results. This is at least partially due to intra-tumor regional heterogeneity in response to treatment. To address this pressing challenge, we combine high-throughput single-cell sequencing with state-of-the-art machine-learning algorithms, to produce quantitative models of tumor heterogeneity and micro-environment interaction. Moreover, brain tumor cells can exhibit phenotypes, and molecular signatures, of cell types found in the developing brain. We are also interested in the role of early-brain developmental programs in brain tumor growth.
July 1, 2022 - June 30, 2026 - An informatics framework for single-cell multi-omics from clinical specimens , PI . Sponsor: NIH/NLM, Sponsor Award ID: R01LM013897
September 1, 2018 - May 30, 2024 - PROJECT HOPE: “High-Grade Glioma-Omics in Pediatric and AYA” , Project PI . Sponsor: NIH/NCI, Sponsor Award ID: P30 CA 82103
July 1, 2022 - June 30, 2023 - Decoding the epigenetic differences between molecular subtypes of pediatric diffuse midline glioma , Project PI . Sponsor: NIH/NCI, Sponsor Award ID: P30 CA 82103
July 1, 2019 - June 30, 2023 - Oncolytic virus to potentiate immune-checkpoint blockade in immunologically cold brain tumors , PI . Sponsor: Department of Defense, Sponsor Award ID: W81XWH-19-1-0348
New York University, New York, NY, BA, 05/97, Mathematics
Cornell University, Ithaca, NY, MS, 05/03, Computer Science
Cornell University, Ithaca, NY, PhD, 05/03, Applied Mathematics